Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: I. In vitro study

Circulation

Volumn 96, Issue 11, 1997, Pages 4011-4018

  Sosunov, Eugene A ^a   Anyukhovsky, Evgeny P ^a   Rosen, Michael R ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Quinidine; Repolarization

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; POTASSIUM ION; QUINIDINE; SODIUM ION; TETRODOTOXIN;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; ENDOCARDIUM; EPICARDIUM; HEART CYCLE; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SODIUM CURRENT;

EID: 0030707554     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.11.4011     Document Type: Article

References (55)

1. Scherf D, Schott A. Extrasystoles and Allied Arrhythmias. Chicago, Ill: William Heinemann Medical Books; 1973.
2. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation. 1991;84:1977-1983.
3. Salerno DM. Quinidine: is it a good drug or a bad drug? Postgrad Med. 1992;92:131-140.
4. Heissenbuttel RH, Bigger JT Jr. The effects of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration. Am Heart J. 1970;80:453-462.
5. Malcolm AD, David GK. Quinidine in cardiology. Acta Leidensia. 1987;55:87-98.
6. Jackman WH, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115-172.
7. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implication for patient care. Am Heart J. 1986;111:1088-1093.
8. Nademanee K, Stevenson WG, Weiss JM, Frame VB, Antimisiaris MG, Suithichaiyakul T, Pruitt CM. Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. Circulation. 1990;81:790-796.
9. Campbell TJ. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983;17:344-352.
10. Clarkson CW, Hondeghem LM. Evidence for specific receptor site for lidocaine, quinidine, and bupivacaine associated with cardiac sodium channels in guinea pig ventricular myocardium. Circ Res. 1985;56:496-506.
11. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentration in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res. 1985;56:857-867.
12. Lee KS, Hume JR, Giles W, Brown AM. Sodium current depression by lidocaine and quinidine in isolated ventricular cells. Nature. 1981;291:325-327.
13. Wu MH, Su MJ, Lue HC. Age-related quinidine effects on ionic currents of rabbit cardiac myocytes. J Mol Cell Cardiol. 1994;26:1167-1177.
14. Mirro MJ, Watanabe AM, Bailey JC. Electrophysiological effects of the optical isomers of disopyramide and quinidine in the dog: dependence on stereochemistry. Circ Res. 1981;48:867-874.
15. Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. Circ Res. 1982;50:17-27.
16. Thompson KA, Blair IA, Woosley RL, Roden DM. Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther. 1987,241:84-90.
17. Roden DM, Iansmith DHS, Woosley RL. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther. 1987;241:84-90.
18. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers: effects of stimulation rate, potassium, and magnesium. Circulation. 1989;79:674-686.
19. Varro A, Nakaya Y, Elharrar V, Surawicz B. Effect of antiarrhythmic drugs on the cycle length-dependent action potential duration in dog Purkinje and ventricular muscle fibers. J Cardiovasc Pharmacol. 1986;8:178-185.
20. Monterro M, Beyer T, Schmitt C, Kubler W, Brachman J. Differential effects of quinidine on transmembrane action potentials of normal and infarcted canine Purkinje fibers. J Cardiovasc Pharmacol. 1992;20:304-310.
21. Carmeliet E, Saikawa T. Shortening of the action potential and reduction of pacemaker activity by lidocaine, quinidine, and procainamide in sheep Purkinje fibers: an effect on Na or K currents? Circ Res. 1982;50:257-272.
22. Burke GH, Loukides JE, Berman ND. Comparative electropharmacology of mexiletine, lidocaine and quinidine in a cardiac Purkinje fiber model. J Pharmacol Exp Ther. 1986;237:232-236.
23. + concentration. Clin Exp Pharmacol Physiol. 1991;18:533-541.
24. Wyse KR, Ye V, Campbell TJ. Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implication for proarrhythntia due to the triggered activity. J Cardiovasc Pharmacol. 1993;21:316-322.
25. Berman ND, Dorian P. Cellular mechanism underlying the efficacy of the sotalol-quinidine combination. J Cardiovasc Pharmacol. 1993;21:609-614.
26. Nawrath H. Action potential, membrane currents and force of contraction in mammalian heart muscle fibers treated with quinidine. J Pharmacol Exp Ther. 1981;216:176-182.
27. Salata JJ, Wasserstrom JA. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. Circ Res. 1988;62:324-337.
28. Nawrath H, Eckel L. Electrophysiological study of human ventricular heart muscle treated with quinidine: interaction with isoprenaline. J Cardiovasc Pharmacol. 1979;1:415-425.
29. Prinzmetal M, Ishikawa K, Oishi H, Ozkan E, Wakayama J, Baines JM. Effects of quinidine on electrical behavior in cardiac muscle. J Pharmacol Exp Ther. 1967;157:659-664.
30. Brugada J, Sassine A, Escande D, Masse C, Puech P. Effects of quinidine on ventricular repolarization. Eur Heart J. 1987;8:1340-1345.
31. Franz MR, Costard A. Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ. Circulation. 1988;77:1177-1184.
32. Duker G, Almgreen O, Carlsson L. Electrophysiological and hemodynamic effects of H234/09 (Almokalant), quinidine, and (+)-sotalol in the anesthetized dog. J Cardiovasc Pharmacol. 1992;20:458-465.
33. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. Circ Res. 1991;68:1729-1741.
34. Sicouri S, Antzelevitch C. Electrophysiologic characteristics of M cells in the canine left ventricular free wall. J Cardiovasc Electrophysiol. 1995;6:591-603.
35. Sicouri S, Antzelevitch C. Afterdepolarization and triggered activity develop in a select population of cells (M cells) in canine ventricular myocardium: the effects of acetylstrophantidin and Bay K8644. Pacing Clin Electrophysiol. 1991;14:1714-1720.
36. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. J Cardiovasc Electrophysiol. 1993;4:48-58.
37. Weissenburger T, Nesterenko VV, Antzelevitch C. Intramural monophasic action potentials (MAP) display steeper APD rate relations and higher sensitivity to class III agents than epicardial and endocardial MAPs: characteristics of the M cells in vivo. Circulation. 1995;92(suppl I):I-300. Abstract.
38. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiologic properties of epicardium, midmyocardium and endocardium: in vitro and in vivo correlations. Circulation. 1996;94:1981-1988.
39. Anyukhovsky EP, Sosunov EA, Rosen MR. Effects of quinidine on repolarization in canine epicardium, midmyocardium and endocardium. II. In vivo study. Circulation. 1997;96:4019-4026.
40. Rosen MR, Merker C, Gelband H, Hoffman BF. Effects of procainamide on the electrophysiological properties of the canine ventricular conducting system. J Pharmacol Exp Ther. 1973;185:438-446.
41. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design. New York, NY: McGraw-Hill Inc; 1991.
42. Wettwer E, Grundke M, Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res. 1992;26:1145-1152.
43. Attwell D, Cohen I, Eisner D, Ohba M, Ojeda C. The steady-state TTX-sensitive ('window') current in cardiac Purkinje fibers. Pflugers Arch. 1979;379:137-142.
44. + channel: role of S6 in antiarrhythmic drug binding. Circ Res. 1996;78:1105-1114.
45. Nattel S, Bailey JC. Time course of the electrophysiological effects of quinidine on canine cardiac Purkinje fibers: concentration dependence and comparison with lidocaine and disopyramide. J Pharmacol Exp Ther. 1983;225:176-180.
46. Neff CA, Davis LE, Baggot JD. A comparative study of the pharmacokinetics of quinidine. Am J Vet Res. 1972;33:1521-1525.
47. Cho YW. Quantitative correlation of plasma and myocardial quinidine concentrations with biochemical and electrocardiographic changes. Am Heart J. 1973;85:648-654.
48. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol. 1987;253:H704-H708.
49. Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther. 1995;272:184-196.
50. Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. Circ Res. 1982;50:17-27.
51. Hiraoka M, Sawada K, Kawano S. Effects of quinidine on plateau currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1986;18:1097-1106.
52. K activation in guinea pig ventricular myocytes. Circ Res. 1988;62:1055-1058.
53. Balser JR, Bennett PB, Hondeghem LM, Roden DM. Suppression of time-dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res. 1991;69:519-529.
54. Coraboeuf E, Deroubaix E, Coulombe A. Effect of tetrodotoxin on action potentials of the conducting system in the dog heart. Am J Physiol. 1979;236:H561-H567.
55. Eddlestone GT, Zygmunt AC, Antzelevitch C. Larger late sodium current contributes to the longer action potential of the M cell in canine ventricular myocardium. Pacing Clin Electrophysiol. 1996;19:569. Abstract.